- May 12, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Empliciti
Synonyms :
Elotuzumab, HuLuc63, Immunoglobulin G1
Class :
Antineoplastics and Monoclonal Antibody
Dosage Forms & Strengths
Injection, lyophilized powder for reconstitution
300mg per vial
400mg per vial
Combination with lenalidomide and dexamethasone :
when lenalidomide and dexamethasone in combination are given to patients who already received 1-3 prior therapies
The one treatment cycle is a 28-day course cycle.
Until disease progression or unacceptable toxicity appears to continue, the course.
Cycles 1-2
• Elotuzumab 10 mg per kg given IV on days 1, 8, 15, and 22
• Lenalidomide 25 mg PO on days 1-21
• Dexamethasone 28 mg PO given 3 to 24 hours before elotuzumab on days 1, 8, 15, and 22
Cycle 3:
• Elotuzumab 10 mg per kg given IV on days 1 and 15
• Lenalidomide 25 mg PO on days 1-21
• Dexamethasone 28 mg PO given 3-24 hours before elotuzumab on days 1 and 15 when elotuzumab has been taken
• Dexamethasone 40 mg PO given on days 8 and 22 when elotuzumab is not given
Combination with pomalidomide and dexamethasone
When pomalidomide and dexamethasone are given in combination for patients who already received 1-3 prior therapies
The one treatment cycle is a 28-day course cycle.
Until disease progression or unacceptable toxicity appears to continue, the course.
Cycles 1-2
• Elotuzumab 10 mg/kg IV on days 1, 8, 15, 22
• Pomalidomide 4 mg PO on days 1-21
• Dexamethasone 28 mg given for less than 75years or 8 mg given more than 75years PO given 3-24hr before elotuzumab given on days 1, 8, 15, and 22 when elotuzumab is administered
Cycle 3:
• Elotuzumab 20 mg per kg IVon day 1
• Pomalidomide 4 mg PO on days 1-21
• Dexamethasone 28 mg given for less than 75years or 8 mg given for more than 75years PO given 3-24hrs before elotuzumab given on Day 1 when elotuzumab is administered
• Dexamethasone 40 mg given for less than 75years or 20 mg given for more than 75years PO given on days 8, 15, and 22 when elotuzumab is not administered
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of severe and potentially fatal infection
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
influenza virus vaccine h n live
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
influenza virus vaccine live trivalent
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
when both drugs are combined, there may be an increased risk or severity of adverse effects
poliovirus vaccine live trivalent
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of nerve damage
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be an increased risk of nerve damage
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be a reduced response to the vaccine
when both drugs are combined, there may be an increased risk of nerve damage
when both drugs are combined, there may be an increased risk of developing rare infections
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be a reduced response to the skin test
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of nerve damage
when both drugs are combined, there may be an increased risk of nerve damage
when both drugs are combined, there may be an increased risk of nerve damage
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a reduced response to the skin test
when both drugs are combined, there may be an increased risk of nerve damage
when both drugs are combined, there may be an increased risk of nerve damage
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of nerve damage
when both drugs are combined, there may be an increased risk of nerve damage
when both drugs are combined, there may be an increased risk of nerve damage
when both drugs are combined, there may be an increased risk of nerve damage
it may enhance the adverse effects when combined with aducanumab
Adverse drug reactions:
Frequency defined
1-10%
Chest pain
Hypersensitivity
Hypoesthesia
Night sweats
Second primary malignancies
>10%
Cataracts
Diarrhea
Constipation
Oropharyngeal pain
Pain in extremities
Decreased appetite
weight loss
Peripheral neuropathy
headache
Lymphopenia
Vomiting
Fatigue
Pyrexia
Cough
nasopharyngitis
upper respiratory tract infection
pneumonia
0.1-1%
Anaphylactic reaction
Frequency not defined
Hyperglycemia
hypocalcemia
low bicarbonate
hyperkalemia
Leukopenia
Thrombocytopenia
Deep vein thrombosis
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Elotuzumab is used to treat multiple myeloma, a form of blood cancer, and treat cancer patients who were previously on medication.
Before starting the treatment, inform your doctor if you have any allergies to food, medicine, or other excipients.
The side effects include nausea, headache, dizziness, itchiness, runny or stuffy nose, fevers, cough, lower abdominal pain, persistent sores, ear pounding, sweating, chills, yellow eyes/skin, and throat tightens or trouble breathing.
There are no studies performed on the secretion of elotuzumab in breast milk; hence the consultation with the doctor is necessary to outweigh the benefits over potential risks in the infants of lactating females.
Store the medication in a cool and moisture-free place away from children and pets.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
